- KR₩291bn
- KR₩484bn
- KR₩160bn
- 12
- 30
- 35
- 11
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.3 | ||
| Price to Tang. Book | 2.5 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.56 | ||
| EV to EBITDA | 59.77 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1.09% | ||
| Return on Equity | -19.84% | ||
| Operating Margin | -2.08% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 115,180.89 | 115,856.07 | 124,880.97 | 144,295.73 | 159,904.29 | n/a | n/a | 11.09% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -83.71 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Amicogen, Inc. is a Korea-based company engaged in the development, production and distribution of enzymes, bio new materials and healthcare food. The Company’s products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The Company distributes its products within domestic market and to overseas markets, including China, Japan, the United Sates, Germany and Thailand.
Directors
- Yong Cheol Shin CEO (53)
- Yeong Su Kim MDR (54)
- Hak Su Kim OTH (56)
- Cheol Park DRC (40)
- Sang Cheol Kim NID (44)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- May 29th, 2000
- Public Since
- September 12th, 2013
- No. of Shareholders
- 24,685
- No. of Employees
- 113
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Korea Exchange - KOSDAQ- Shares in Issue
- 54,816,218
- Address
- 14-10, JINJU, 52840
- Web
- http://www.amicogen.com/
- Phone
- +82 557596161
- Auditors
- LIAN Accounting Corporation
Upcoming Events for 092040
Q3 2024 Amicogen Inc Earnings Release
Similar to 092040
ABion
Korea Exchange - KOSDAQ
ABL Bio
Korea Exchange - KOSDAQ
ADM Korea
Korea Exchange - KOSDAQ
AprilBio Co
Korea Exchange - KOSDAQ
AptaBio Therapeutics
Korea Exchange - KOSDAQ
FAQ
What is the Amicogen share price?
As of Today at 13:16 UTC, shares in Amicogen are trading at KR₩7,290. This share price information is delayed by 15 minutes.
How has the Amicogen share price performed this year?
Shares in Amicogen last closed at KR₩7,290 and the price had moved by -16.67% over the past 365 days. In terms of relative price strength the Amicogen share price has underperformed the FTSE Developed Asia Pacific Index by -18.62% over the past year.
What are the analyst and broker recommendations for Amicogen?
The overall consensus recommendation for Amicogen is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Amicogen dividend yield?
Amicogen does not currently pay a dividend.
Does Amicogen pay a dividend?
Amicogen does not currently pay a dividend.
When does Amicogen next pay dividends?
Amicogen does not currently pay a dividend.
How do I buy Amicogen shares?
To buy shares in Amicogen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Amicogen?
As of the previous close price of KR₩7,290, shares in Amicogen had a market capitalisation of KR₩400bn.
Where are Amicogen shares listed?
Here are the trading details for Amicogen:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 092040
What kind of share is Amicogen?
Based on an overall assessment of its quality, value and momentum Amicogen is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Amicogen share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Amicogen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Amicogen. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +0.25%.
As of the last closing price of KR₩7,290, shares in Amicogen were trading +6.02% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Amicogen PE Ratio?
The Amicogen PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩7,290.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Amicogen?
Amicogen's management team is headed by:
- Yong Cheol Shin - CEO
- Yeong Su Kim - MDR
- Hak Su Kim - OTH
- Cheol Park - DRC
- Sang Cheol Kim - NID